IL238143B - Antibody-drug conjugate - Google Patents

Antibody-drug conjugate

Info

Publication number
IL238143B
IL238143B IL238143A IL23814315A IL238143B IL 238143 B IL238143 B IL 238143B IL 238143 A IL238143 A IL 238143A IL 23814315 A IL23814315 A IL 23814315A IL 238143 B IL238143 B IL 238143B
Authority
IL
Israel
Prior art keywords
antibody
drug conjugate
conjugate
drug
Prior art date
Application number
IL238143A
Other languages
Hebrew (he)
Other versions
IL238143A0 (en
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50477169&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL238143(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of IL238143A0 publication Critical patent/IL238143A0/en
Publication of IL238143B publication Critical patent/IL238143B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
IL238143A 2012-10-11 2015-04-02 Antibody-drug conjugate IL238143B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012225887 2012-10-11
PCT/JP2013/006069 WO2014057687A1 (en) 2012-10-11 2013-10-10 Antibody-drug conjugate

Publications (2)

Publication Number Publication Date
IL238143A0 IL238143A0 (en) 2015-05-31
IL238143B true IL238143B (en) 2020-01-30

Family

ID=50477169

Family Applications (5)

Application Number Title Priority Date Filing Date
IL313147A IL313147A (en) 2012-10-11 2013-10-10 Antibody-drug conjugates and methods for their preparation
IL302494A IL302494B2 (en) 2012-10-11 2013-10-10 Antibody-Drug Conjugates and Methods of Producing Same
IL271760A IL271760B (en) 2012-10-11 2013-10-10 Antibody-drug conjugates and methods of producing same
IL294622A IL294622B2 (en) 2012-10-11 2013-10-10 Antibody-Drug Conjugates and Methods of Producing Same
IL238143A IL238143B (en) 2012-10-11 2015-04-02 Antibody-drug conjugate

Family Applications Before (4)

Application Number Title Priority Date Filing Date
IL313147A IL313147A (en) 2012-10-11 2013-10-10 Antibody-drug conjugates and methods for their preparation
IL302494A IL302494B2 (en) 2012-10-11 2013-10-10 Antibody-Drug Conjugates and Methods of Producing Same
IL271760A IL271760B (en) 2012-10-11 2013-10-10 Antibody-drug conjugates and methods of producing same
IL294622A IL294622B2 (en) 2012-10-11 2013-10-10 Antibody-Drug Conjugates and Methods of Producing Same

Country Status (30)

Country Link
US (6) US10195288B2 (en)
EP (3) EP3342785B1 (en)
JP (9) JP5953378B2 (en)
KR (15) KR102369419B1 (en)
CN (4) CN113929738B (en)
AU (5) AU2013328111B2 (en)
BR (3) BR112015006521B1 (en)
CA (2) CA3021435C (en)
CY (2) CY1120363T1 (en)
DK (2) DK3342785T3 (en)
ES (2) ES2773710T3 (en)
HR (2) HRP20180870T1 (en)
HU (2) HUE048748T2 (en)
IL (5) IL313147A (en)
LT (2) LT2907824T (en)
MX (3) MX364484B (en)
MY (1) MY170251A (en)
NZ (4) NZ746440A (en)
PH (2) PH12015500667B1 (en)
PL (2) PL2907824T3 (en)
PT (2) PT3342785T (en)
RS (2) RS60000B1 (en)
RU (1) RU2664465C2 (en)
SG (2) SG10201804788XA (en)
SI (2) SI3342785T1 (en)
SM (2) SMT201800344T1 (en)
TR (1) TR201809636T4 (en)
TW (16) TWI696611B (en)
WO (1) WO2014057687A1 (en)
ZA (2) ZA201501825B (en)

Families Citing this family (225)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2773710T3 (en) 2012-10-11 2020-07-14 Daiichi Sankyo Co Ltd Linkers for antibody-drug conjugates
WO2014061277A1 (en) * 2012-10-19 2014-04-24 第一三共株式会社 Antibody-drug conjugate produced by binding through linker having hydrophilic structure
AU2014371934B2 (en) 2013-12-25 2020-01-23 Daiichi Sankyo Company, Limited Anti-TROP2 antibody-drug conjugate
IL310627B2 (en) 2014-01-31 2026-04-01 Daiichi Sankyo Co Ltd Anti-her2 antibody-drug conjugates, compositions comprising same and uses thereof
JP2017114763A (en) * 2014-03-26 2017-06-29 第一三共株式会社 Anti-CD98 antibody-drug conjugate
EP3130608B1 (en) * 2014-04-10 2019-09-04 Daiichi Sankyo Co., Ltd. (anti-her2 antibody)-drug conjugate
KR102445502B1 (en) * 2014-04-10 2022-09-21 다이이찌 산쿄 가부시키가이샤 Anti-her3 antibody-drug conjugate
CN116059395A (en) 2015-06-29 2023-05-05 第一三共株式会社 Methods for the selective manufacture of antibody-drug conjugates
CN108779338A (en) * 2015-12-24 2018-11-09 Ａｇｃ株式会社 Resin combination, base material and cell culture processes
GEP20227398B (en) * 2016-04-15 2022-07-25 Macrogenics Inc Novel b7-h3 binding molecules, antibody drug conjugates thereof and usage thereof
WO2017214322A1 (en) * 2016-06-08 2017-12-14 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
AU2017279550A1 (en) * 2016-06-08 2019-01-03 Abbvie Inc. Anti-B7-H3 antibodies and antibody drug conjugates
CN107840892A (en) * 2016-09-20 2018-03-27 上海药明生物技术有限公司 Novel Anti-PCSK9 Antibody
US11273155B2 (en) 2016-12-12 2022-03-15 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and immune checkpoint inhibitor
JP6679762B2 (en) * 2017-01-17 2020-04-15 第一三共株式会社 Anti-GPR20 antibody and anti-GPR20 antibody-drug conjugate
CN117982673A (en) 2017-02-28 2024-05-07 第一三共株式会社 Application of anti-HER3 antibody-drug conjugates
TW202532104A (en) * 2017-05-15 2025-08-16 日商第一三共股份有限公司 Antibody-drug conjugates and use thereof
CN109963591B (en) * 2017-08-04 2023-04-04 江苏恒瑞医药股份有限公司 B7H3 antibody-drug conjugate and medical application thereof
WO2019034176A1 (en) * 2017-08-18 2019-02-21 四川百利药业有限责任公司 Camptothecin-antibody conjugate
AU2018320470B2 (en) 2017-08-23 2025-04-24 Daiichi Sankyo Company, Limited Antibody-drug conjugate preparation and lyophilization for same
CA3074208C (en) 2017-08-31 2023-10-03 Daiichi Sankyo Company, Limited Novel method for producing antibody-drug conjugate
IL324591A (en) * 2017-08-31 2026-01-01 Daiichi Sankyo Co Ltd Improved methods for producing antibody-drug conjugate
NZ762505A (en) 2017-09-29 2026-03-27 Daiichi Sankyo Co Ltd Antibody-pyrrolobenzodiazepine derivative conjugate
WO2019154120A1 (en) * 2018-02-11 2019-08-15 四川科伦博泰生物医药股份有限公司 Cytotoxic agent and conjugate thereof, preparation method therefor and use thereof
BR112020020466A2 (en) * 2018-04-06 2021-01-12 Seattle Genetics, Inc. CAMPTOTECIN PEPTIDE CONJUGATES
SG11202010496WA (en) 2018-05-18 2020-12-30 Daiichi Sankyo Co Ltd Anti-muc1 antibody-drug conjugate
KR20210035805A (en) 2018-06-15 2021-04-01 플래그쉽 파이어니어링 이노베이션스 브이, 인크. Increased immune activity through regulation of postcellular signaling factors
SG11202100653YA (en) 2018-07-25 2021-02-25 Daiichi Sankyo Co Ltd Effective method for manufacturing antibody-drug conjugate
WO2020022475A1 (en) 2018-07-27 2020-01-30 第一三共株式会社 Protein recognizing drug moiety of antibody-drug conjugate
CA3108044A1 (en) 2018-07-31 2020-02-06 Daiichi Sankyo Company, Limited Treatment of metastatic brain tumor by administration of antibody-drug conjugate
EA202190471A1 (en) * 2018-08-06 2021-05-24 Дайити Санкио Компани, Лимитед COMBINATION OF ANTIBODY-DRUG CONJUGATE AND TUBULIN INHIBITOR
CN112739826A (en) 2018-08-23 2021-04-30 第一三共株式会社 Sensitivity markers for antibody-drug conjugates
EP3848054B1 (en) 2018-09-06 2025-01-29 Daiichi Sankyo Company, Limited Antibody-drug conjugates of cyclic dinucleotide derivatives
WO2020059772A1 (en) 2018-09-20 2020-03-26 第一三共株式会社 Treatment of her3 mutant cancer by administration of anti-her3 antibody-drug conjugate
WO2020063676A1 (en) * 2018-09-26 2020-04-02 江苏恒瑞医药股份有限公司 Ligand-drug conjugate of exatecan analogue, preparation method therefor and application thereof
CA3114474A1 (en) 2018-09-30 2020-04-02 Jiangsu Hengrui Medicine Co., Ltd. Anti-b7h3 antibody-exatecan analog conjugate and medicinal use thereof
SG11202104993SA (en) 2018-11-14 2021-06-29 Daiichi Sankyo Co Ltd Anti-cdh6 antibody-pyrrolobenzodiazepine derivative conjugate
KR102905497B1 (en) 2018-12-11 2025-12-30 다이이찌 산쿄 가부시키가이샤 Combination of antibody-drug conjugates and PARP inhibitors
US20220040324A1 (en) * 2018-12-21 2022-02-10 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
DK3941946T3 (en) 2019-03-20 2025-03-24 Univ California CLAUDIN-6 ANTIBODIES AND DRUG CONJUGATES
US20220177583A1 (en) 2019-03-20 2022-06-09 The Regents Of The University Of California Claudin-6 bispecific antibodies
MX2021011812A (en) 2019-03-29 2021-10-22 Medimmune Ltd COMPOUNDS AND CONJUGATES OF THESE.
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
CN111689980A (en) * 2019-05-26 2020-09-22 四川百利药业有限责任公司 Camptothecin drug and antibody conjugate thereof
CN113766933B (en) * 2019-06-28 2024-09-06 上海复旦张江生物医药股份有限公司 Antibody-coupled drug, intermediate, preparation method and application thereof
CN112138171B (en) * 2019-06-28 2024-09-24 泰州复旦张江药业有限公司 Antibody-drug conjugates, intermediates thereof, preparation methods and applications
MX2022000449A (en) 2019-07-10 2022-04-25 Cybrexa 2 Inc PEPTIDE CONJUGATES OF CYTOTOXINS AS THERAPEUTIC.
US11555019B2 (en) 2019-07-10 2023-01-17 Cybrexa 3, Inc. Peptide conjugates of microtubule-targeting agents as therapeutics
CN112125915A (en) * 2019-09-18 2020-12-25 四川百利药业有限责任公司 A kind of camptothecin derivative and its conjugate
US20230054458A1 (en) * 2019-12-12 2023-02-23 Jiangsu Hengrui Medicine Co., Ltd. Anti-claudin antibody-drug conjugate and pharmaceutical use thereof
KR20220113747A (en) * 2019-12-16 2022-08-16 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 Conjugates of anti-CEA antibody-exatecan analogs and pharmaceutical uses thereof
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
JP7821733B2 (en) 2020-01-22 2026-02-27 上海森輝医薬有限公司 Drug conjugate of eribulin derivative, its preparation method and medical application
JP7781064B2 (en) 2020-01-22 2025-12-05 江蘇恒瑞医薬股▲ふん▼有限公司 Anti-TROP-2 antibody-exatecan analog conjugate and its pharmaceutical use
WO2021173773A1 (en) 2020-02-25 2021-09-02 Mediboston, Inc. Camptothecin derivatives and conjugates thereof
IL296124A (en) 2020-03-06 2022-11-01 Daiichi Sankyo Co Ltd Conjugation of an antibody with a drug including a novel cyclic dinucleotide derivative
CN115298220B (en) * 2020-03-24 2024-12-20 上海翰森生物医药科技有限公司 Antibody-drug conjugates and their medical uses
CN115605510A (en) * 2020-03-25 2023-01-13 江苏豪森药业集团有限公司（Cn） B7H3 antibody-Exitecan analogue conjugate and its medical application
MX2022011808A (en) * 2020-03-25 2022-12-06 Jiangsu Hengrui Pharmaceuticals Co Ltd Anti-psma antibody-exatecan analogue conjugate and medical use thereof.
BR112022019073A2 (en) * 2020-03-25 2022-11-08 Jiangsu Hengrui Pharmaceuticals Co Ltd PHARMACEUTICAL COMPOSITION INCLUDING ANTIBODY-DRUG CONJUGATE AND USE THEREOF
CN115103858B (en) * 2020-03-25 2025-07-15 江苏恒瑞医药股份有限公司 A method for preparing an antibody-drug conjugate
CN115348971A (en) * 2020-03-30 2022-11-15 国立研究开发法人国立癌症研究中心 Antibody-drug conjugates
AU2021289927A1 (en) * 2020-06-08 2023-01-19 Systimmune, Inc. Camptothecin drug having high-stability hydrophilic connecting unit and conjugate thereof
EP4171654A1 (en) 2020-06-24 2023-05-03 AstraZeneca UK Limited Combination of antibody-drug conjugate and cdk9 inhibitor
IL299368A (en) 2020-06-24 2023-02-01 Astrazeneca Uk Ltd Combination of antibody-drug conjugate and atr inhibitor
WO2021260582A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and aurora b inhibitor
WO2021260583A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and dna-pk inhibitor
US20230256110A1 (en) 2020-06-24 2023-08-17 Astrazeneca Uk Limited Combination of antibody-drug conjugate and atm inhibitor
US20230355804A1 (en) 2020-06-29 2023-11-09 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
US10997243B1 (en) 2020-06-30 2021-05-04 Snowflake Inc. Supporting unstructured, semi-structured, and structured files
US11361026B2 (en) 2020-06-30 2022-06-14 Snowflake Inc. Accessing files in a database stage using a user defined function
US11423081B1 (en) 2020-06-30 2022-08-23 Snowflake Inc. Accessing files in a database stage using a user defined function
EP4175672A1 (en) 2020-07-06 2023-05-10 Byondis B.V. Antifolate linker-drugs and antibody-drug conjugates
EP4178559A4 (en) * 2020-07-10 2025-03-05 Velosbio Inc. NOVEL ROR1 ANTIBODY IMMUNOCONJUGATES
CN116390771A (en) * 2020-07-13 2023-07-04 瑞泽恩制药公司 Camptothecin analogs conjugated to glutamine residues in proteins and uses thereof
IL299803A (en) 2020-07-17 2023-03-01 Daiichi Sankyo Co Ltd Method for producing antibody-drug conjugate
EP4183421A4 (en) 2020-08-13 2025-04-23 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. ANTIBODY-DRUG CONJUGATE
KR20230050378A (en) 2020-08-13 2023-04-14 이나뜨 파르마 에스.에이. Methods of Treating Cancer Using Anti-CD73 Antibodies
WO2022050300A1 (en) 2020-09-02 2022-03-10 第一三共株式会社 NOVEL ENDO-β-N-ACETYLGLUCOSAMINIDASE
JP2023551355A (en) 2020-09-30 2023-12-08 デュアリティ バイオロジクス（スーチョウ）カンパニー，リミティド Antitumor compounds and methods of preparation and use thereof
JP2023545096A (en) 2020-10-09 2023-10-26 アストラゼネカ ユーケー リミテッド Combination of antibody-drug conjugates and PARP1 selective inhibitors
US20250276078A1 (en) * 2020-10-12 2025-09-04 Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. Camptothecin Derivative And Ligand-drug Conjugate Thereof
JP7753372B2 (en) * 2020-10-12 2025-10-14 シーチュアン バイリ ファーム シーオー． エルティーディー Deuterated camptothecin derivatives and antibody-drug conjugates thereof
AU2021378152A1 (en) 2020-11-11 2023-06-22 Daiichi Sankyo Company, Limited COMBINATION OF AN ANTIBODY-DRUG CONJUGATE WITH ANTI-SIRPα ANTIBODY
CN116615250A (en) 2020-11-12 2023-08-18 第一三共株式会社 Mesothelioma treatment by administration of anti-B7-H3 antibody-drug conjugates
WO2022099762A1 (en) * 2020-11-12 2022-05-19 博瑞生物医药（苏州）股份有限公司 Antibody conjugate intermediate and preparation method therefor
EP4265275A4 (en) * 2020-12-18 2024-03-20 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Trop2 targeting antibody-drug conjugate, and preparation method and use therefor
JP7564958B2 (en) * 2020-12-18 2024-10-09 シャンハイ フダン－チャンジャン バイオ－ファーマシューティカル カンパニー リミテッド Antibody-drug conjugates targeting B7-H3, methods of manufacture and uses thereof - Patents.com
WO2022140504A1 (en) * 2020-12-23 2022-06-30 Shanghai Ruotuo Biosciences Co., Ltd. Antibody-drug conjugates, pharmaceutical compositions, and therapeutic applications
MX2023008285A (en) 2021-01-13 2023-09-12 Memorial Sloan Kettering Cancer Center Anti-dll3 antibody-drug conjugate.
CN114805377A (en) * 2021-01-29 2022-07-29 明慧医药（杭州）有限公司 Toxin molecules suitable for antibody-drug conjugates
TW202241454A (en) 2021-02-01 2022-11-01 日商第一三共股份有限公司 Novel method for producing antibody-immunostimulator conjugate
EP4257154A4 (en) 2021-02-09 2026-04-22 Medilink Therapeutics Suzhou Co Ltd Bioactive substance conjugate, method of preparation and use thereof
US12521444B2 (en) 2021-02-25 2026-01-13 Fortvita Biologics Limited Anti-HER2 antibody-drug conjugates and uses thereof
US20240279364A1 (en) 2021-03-12 2024-08-22 Daiichi Sankyo Company, Limited Glycan, and method for producing medicine containing glycan
CN117015549A (en) * 2021-03-17 2023-11-07 江苏恒瑞医药股份有限公司 A kind of preparation method of camptothecin derivatives
BR112023018676A2 (en) 2021-03-18 2023-10-10 Seagen Inc ANTIBODY-DRUG CONJUGATE, PHARMACEUTICAL COMPOSITION, METHODS OF TREATMENT OF A DISEASE OR CONDITION AND A CANCER, AND, LINDER-DRUG CONJUGATE COMPOSITION
EP4313109A1 (en) 2021-03-31 2024-02-07 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
CN115197234A (en) * 2021-04-02 2022-10-18 江苏恒瑞医药股份有限公司 A kind of preparation method of camptothecin derivative intermediate
US20240209080A1 (en) 2021-04-10 2024-06-27 Profoundbio Us Co. Folr1 binding agents, conjugates thereof and methods of using the same
CN117177775A (en) * 2021-04-14 2023-12-05 启德医药科技（苏州）有限公司 Linkers, conjugates and their applications
EP4079327A1 (en) 2021-04-22 2022-10-26 Centaurus Polytherapeutics Payloads for drug-conjugates and their use for treating cancer
CA3216459A1 (en) 2021-04-23 2022-10-27 Profoundbio Us Co. Anti-cd70 antibodies, conjugates thereof and methods of using the same
TW202302649A (en) * 2021-04-26 2023-01-16 大陸商江蘇恆瑞醫藥股份有限公司 Anti-nectin-4 antibody, anti-nectin-4 antibody-drug conjugate and medicinal use thereof
CN113816969B (en) * 2021-04-30 2024-01-16 联宁（苏州）生物制药有限公司 Eptification control compound, antibody drug conjugate thereof and application thereof
US11645243B2 (en) 2021-06-07 2023-05-09 Snowflake Inc. Accessing files in a database stage using a user defined function
IL309457A (en) * 2021-06-17 2024-02-01 Minghui Pharmaceutical Hangzhou Ltd Antitumor compound and use thereof
EP4362982A1 (en) 2021-06-28 2024-05-08 Byondis B.V. Conjugates comprising phosphoantigens and their use in therapy
AU2022303363A1 (en) 2021-06-29 2024-01-18 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
TW202320857A (en) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 Linkers, drug linkers and conjugates thereof and methods of using the same
CN113402584A (en) * 2021-07-06 2021-09-17 联宁（苏州）生物制药有限公司 Synthetic method of intermediate LND1067-L1 of antibody-coupled drug linker
CN113527418B (en) * 2021-07-16 2022-05-03 成都普康唯新生物科技有限公司 Preparation method of ADC linker
TW202320858A (en) 2021-07-19 2023-06-01 美商薩諾管理公司 Immunoconjugates and methods
CN117715913A (en) * 2021-07-19 2024-03-15 芝诺管理公司 Immunoconjugates and methods
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
CA3225598A1 (en) 2021-07-21 2023-01-26 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition containing anti-trop2 antibody drug conjugate and its application
MX2024003277A (en) 2021-09-15 2024-04-04 Daiichi Sankyo Co Ltd ANTIBODY-DRUG CONJUGATE FOR USE IN METHODS OF TREATING CHEMOTHERAPY-RESISTANT CANCER.
CA3234692A1 (en) 2021-09-30 2023-04-06 Ajinomoto Co., Inc. Conjugate of antibody and functional substance or salt thereof, and antibody derivative and compound used in production of the same or salts thereof
KR20240099178A9 (en) 2021-10-18 2025-12-10 다이이찌 산쿄 가부시키가이샤 anti-CD37 antibody-drug conjugate
EP4426727A2 (en) 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
WO2023083381A1 (en) 2021-11-15 2023-05-19 成都百利多特生物药业有限责任公司 Bispecific antibody-camptothecin drug conjugate and pharmaceutical use thereof
US11814394B2 (en) 2021-11-16 2023-11-14 Genequantum Healthcare (Suzhou) Co., Ltd. Exatecan derivatives, linker-payloads, and conjugates and thereof
AU2022392822A1 (en) 2021-11-18 2024-05-02 Astrazeneca Uk Limited Combination of antibody-drug conjugate and parp1 selective inhibitor
WO2023092099A1 (en) 2021-11-19 2023-05-25 Ardeagen Corporation Gpc3 binding agents, conjugates thereof and methods of using the same
IL312728A (en) 2021-11-30 2024-07-01 Daiichi Sankyo Co Ltd Antibodies masked in protease-wells
WO2023098889A1 (en) 2021-12-03 2023-06-08 成都百利多特生物药业有限责任公司 Anti-human trop2 antibody-camptothecin drug conjugate and medical use thereof
CA3241157A1 (en) * 2021-12-16 2023-06-22 Wei Zhou Camptothecin compound and conjugate thereof
CA3240378A1 (en) 2021-12-23 2023-06-29 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-dll3 antibody and pharmaceutical use thereof, and antibody-drug conjugate containing anti-dll3 antibody
US20250059274A1 (en) * 2021-12-24 2025-02-20 Bio-Thera Solutions, Ltd. ANTI-FRa ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF
EP4456899A1 (en) 2021-12-28 2024-11-06 AstraZeneca UK Limited Combination of antibody-drug conjugate and rasg12c inhibitor
CA3240724A1 (en) 2021-12-28 2023-07-06 Astrazeneca Uk Limited Combination of antibody-drug conjugate and atr inhibitor
EP4457229A1 (en) 2021-12-30 2024-11-06 Byondis B.V. Antifolate linker-drugs and antibody-drug conjugates
CN118829450A (en) * 2022-01-18 2024-10-22 甘李药业股份有限公司 An exotecan derivative-antibody conjugate and its medical use
IL314470A (en) 2022-01-25 2024-09-01 Medilink Therapeutics Suzhou Co Ltd Antibody against her3, conjugate and use thereof
TW202342106A (en) 2022-02-09 2023-11-01 日商第一三共股份有限公司 Environment-responsive masked antibodies and use thereof
WO2023163227A1 (en) 2022-02-28 2023-08-31 Ｕｂｅ株式会社 Antibody-drug conjugate
EP4487874A1 (en) 2022-02-28 2025-01-08 UBE Corporation Antibody-drug conjugate precursor and intermediate for synthesis thereof
CN118804983A (en) 2022-03-02 2024-10-18 第一三共株式会社 Method for producing Fc-containing molecules
EP4489790A1 (en) 2022-03-10 2025-01-15 Vivasor, Inc. Antibody-drug conjugates and uses thereof
CN118891525A (en) 2022-03-16 2024-11-01 阿斯利康(英国)有限公司 Scoring method for anti-TROP 2 antibody-drug conjugate therapy
WO2023174401A1 (en) 2022-03-18 2023-09-21 映恩生物制药（苏州）有限公司 Anti-gpc3 antibody drug conjugate and use thereof
CN119317447A (en) 2022-04-12 2025-01-14 米纳瓦生物技术公司 Anti-variable MUC1* antibodies and their uses
EP4514391A1 (en) 2022-04-27 2025-03-05 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor
CN119403829A (en) 2022-05-11 2025-02-07 第一三共株式会社 Combination of tumor antigen-specific antibodies and CD47 inhibitors
CN119255825A (en) 2022-05-24 2025-01-03 第一三共株式会社 Dosing regimens for anti-CDH6 antibody-drug conjugates
AU2023279443A1 (en) 2022-06-03 2025-01-23 Ube Corporation Antibody-multidrug conjugate
WO2023234427A1 (en) 2022-06-03 2023-12-07 Ｕｂｅ株式会社 Antibody-multidrug conjugate precursor and synthetic intermediate thereof
CN119384296A (en) 2022-06-07 2025-01-28 映恩生物制药（苏州）有限公司 Anti-B7H3 antibody-drug conjugates and uses thereof
CA3258612A1 (en) * 2022-06-09 2023-12-14 Beigene, Ltd. ANTIBODY-DRUG CONJUGATES
CA3258214A1 (en) 2022-06-15 2025-03-18 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. A pharmaceutical composition containing an antibody-drug conjugate and its use
WO2024008102A1 (en) * 2022-07-05 2024-01-11 Wuxi Xdc (Shanghai) Co., Ltd. Linker for conjugation
CN115160403B (en) * 2022-07-05 2025-06-27 博石丰生命科技(南通)有限公司 Specific topoisomerase inhibitor and antibody-drug conjugate and preparation method thereof
EP4538276A1 (en) 2022-07-11 2025-04-16 Pinotbio, Inc. Ddx5 protein-binding camptothecin derivatives and prodrugs thereof
WO2024012524A1 (en) 2022-07-14 2024-01-18 苏州宜联生物医药有限公司 Antibody-drug conjugate, and preparation method therefor and use thereof
IL318296A (en) 2022-07-15 2025-03-01 Genequantum Healthcare Suzhou Co Ltd Anti-trop2 antibody and conjugate thereof
EP4558506A1 (en) * 2022-07-22 2025-05-28 NJ Bio, Inc. Hexacyclic topoisomerase inhibitors having cytotoxic activity on cancer cells
JP2025524970A (en) 2022-07-27 2025-08-01 明慧医藥（杭州）有限公司 Antibody-drug conjugates and uses thereof
TW202412859A (en) 2022-07-28 2024-04-01 英商阿斯特捷利康英國股份有限公司 Combination of antibody-drug conjugate and bispecific checkpoint inhibitor
CN117510515A (en) * 2022-07-28 2024-02-06 明慧医药（杭州）有限公司 Toxin molecules suitable for antibody-drug conjugates
EP4566632A1 (en) 2022-08-02 2025-06-11 Nona Biosciences (Suzhou) Co., Ltd. Msln antibody-drug conjugate
AU2023328010A1 (en) 2022-08-25 2025-03-20 Genequantum Healthcare (Suzhou) Co., Ltd. Pharmaceutical composition of antibody drug conjugate
KR20250054799A (en) 2022-08-29 2025-04-23 다이이찌 산쿄 가부시키가이샤 Antibody drug conjugates comprising a mutant Fc region
US20240116945A1 (en) 2022-09-02 2024-04-11 Merck Sharp & Dohme Llc Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof
KR20250064682A (en) 2022-09-09 2025-05-09 다이이찌 산쿄 가부시키가이샤 Novel oligosaccharides, intermediates for producing the oligosaccharides, and methods for producing them
CN117752813A (en) 2022-09-26 2024-03-26 成都百利多特生物药业有限责任公司 Anti-CD33 antibodies and anti-CD33 antibody-drug conjugates and their uses
US20260102506A1 (en) * 2022-09-26 2026-04-16 Solve Therapeutics, Inc. Compositions and uses thereof
KR20250069963A (en) * 2022-09-30 2025-05-20 베이진 스위찰랜드 게엠베하 Ligand-drug conjugates of exatecan analogues and their medical uses
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
WO2024078449A1 (en) 2022-10-09 2024-04-18 LaNova Medicines Limited Compounds, compositions and methods
WO2024091437A1 (en) * 2022-10-25 2024-05-02 Merck Sharp & Dohme Llc Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof
TW202434306A (en) 2022-11-24 2024-09-01 瑞士商百濟神州瑞士有限責任公司 Anti-cea antibody drug conjugates and methods of use
KR20250111373A (en) * 2022-11-25 2025-07-22 밍훼이 파마슈티컬 (항저우) 리미티드 Antitumor compounds and their applications
WO2024114318A1 (en) * 2022-11-29 2024-06-06 四川科伦博泰生物医药股份有限公司 Drug linker compound, preparation method therefor, and use thereof
TW202440169A (en) 2022-11-30 2024-10-16 日商第一三共股份有限公司 Combination of antibody-drug conjugates and dnmt inhibitors
CN116621927B (en) * 2023-01-09 2024-03-26 联宁（苏州）生物制药有限公司 Antibody coupling intermediate with irinotecan and C-lock fixed-point coupling group, coupling method and antibody coupling drug
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
AU2024218327A1 (en) 2023-02-09 2025-09-25 Beone Medicines I Gmbh Self-stabilizing linker conjugates
IL322887A (en) * 2023-02-27 2025-10-01 Suzhou Suncadia Biopharmaceuticals Co Ltd Anti-dll3 antibody, and antibody-drug conjugate and pharmaceutical use thereof
WO2024190815A1 (en) 2023-03-14 2024-09-19 第一三共株式会社 Combination of anti-cdh6 antibody-drug conjugate with vegf inhibitor
CN118666946A (en) * 2023-03-15 2024-09-20 上海亲合力生物医药科技股份有限公司 Linker and conjugated drug using the same, antibody conjugated drug and application thereof
CN120957753A (en) * 2023-03-23 2025-11-14 广州百济神州生物制药有限公司 Bioactive conjugates, their preparation methods and their uses
TW202444760A (en) 2023-03-29 2024-11-16 日商第一三共股份有限公司 Anti-cd25 antibody and drug conjugate thereof
AU2024248799A1 (en) 2023-03-31 2025-10-23 Daiichi Sankyo Company, Limited Combination of anti-CDH6 antibody-drug conjugate and HIF-2alpha inhibitor
WO2024210154A1 (en) 2023-04-04 2024-10-10 味の素株式会社 Antibody-functional substance conjugate, antibody derivative, and compound, or salts thereof
CN121969398A (en) 2023-04-05 2026-05-01 维硕公司 Antibody-drug conjugates and their uses
TW202506190A (en) 2023-04-05 2025-02-16 日商第一三共股份有限公司 Method for treating drug-low-sensitive cancer by administration of anti-muc1 antibody-drug conjugate
WO2024211235A1 (en) 2023-04-05 2024-10-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
CN121969397A (en) 2023-04-05 2026-05-01 维硕公司 Antibody-conjugated drugs and uses thereof
CN121039143A (en) 2023-04-05 2025-11-28 味之素株式会社 Conjugates of antibodies and functional substances or their salts, as well as antibody intermediates or their salts containing thiol groups.
JPWO2024214685A1 (en) 2023-04-10 2024-10-17
KR20260027874A (en) 2023-04-13 2026-03-03 진콴텀 헬스케어 (쑤저우) 씨오., 엘티디. Combination of antibody-drug conjugate and anti-PD-1 antibody and use thereof
EP4699622A1 (en) 2023-04-19 2026-02-25 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and other medicine
AU2024263367A1 (en) 2023-04-27 2025-11-13 CSPC Megalith Biopharmaceutical Co., Ltd. Antibody-drug conjugate
IL324475A (en) 2023-05-06 2026-01-01 Shanghai Qilu Pharmaceutical Res And Development Centre Ltd Deuterated camptothecin compound, and preparation therefor and use thereof
CN121194979A (en) 2023-05-08 2025-12-23 甘李药业股份有限公司 Camptothecin derivatives, linkers, ligand-drug conjugates and their pharmaceutical uses
AU2024273972A1 (en) * 2023-05-16 2025-12-04 CSPC Megalith Biopharmaceutical Co., Ltd. Pharmaceutical composition comprising antibody-drug conjugate
WO2024235071A1 (en) * 2023-05-16 2024-11-21 Nanjing University Conjugate and the preparation thereof
EP4721766A1 (en) 2023-06-02 2026-04-08 Daiichi Sankyo Company, Limited Combination of (anti-her3 antibody)-drug conjugate and rasg12c inhibitor
KR20260020468A (en) 2023-06-05 2026-02-11 장쑤 맵웰 헬스 파마수티컬 알앤디 컴퍼니, 리미티드 Anti-B7-H3 antibody or fragment thereof and antibody drug conjugate targeting B7-H3
WO2025002310A1 (en) * 2023-06-29 2025-01-02 石药集团巨石生物制药有限公司 Antibody-drug conjugate and use thereof
EP4737483A1 (en) 2023-06-30 2026-05-06 Daiichi Sankyo Company, Limited Antibody-drug conjugate production method including purification step using activated carbon material
CN121487754A (en) 2023-07-25 2026-02-06 江苏恒瑞医药股份有限公司 Antibody-drug conjugates targeting c-Met and their pharmaceutical applications
WO2025036480A1 (en) * 2023-08-16 2025-02-20 中山康方生物医药有限公司 Compound and antibody-drug conjugate comprising same
TW202528311A (en) 2023-09-13 2025-07-16 日商安斯泰來製藥股份有限公司 Antibody-drug complex comprising a heterocyclic compound having a G12D mutant KRAS protein degradation inducing effect
AR133955A1 (en) 2023-09-26 2025-11-19 Profoundbio Us Co PTK7 BINDING AGENTS, CONJUGATES THEREOF AND METHODS OF USE THEREOF
WO2025088496A1 (en) 2023-10-24 2025-05-01 Astrazeneca Uk Limited Combination of antibody-drug conjugate and anti-pd-1/tim-3 bispecific binding protein
WO2025106278A1 (en) 2023-11-17 2025-05-22 Mersana Therapeutics, Inc. Treatment of cancer using b7-h4-targeted antibody-drug conjugates
TW202535479A (en) 2023-12-05 2025-09-16 英商阿斯特捷利康英國股份有限公司 Combination of antibody-drug conjugate and blood brain barrier-penetrant parp1 selective inhibitor
WO2025141153A1 (en) 2023-12-29 2025-07-03 Oncomatryx Biopharma, S.L. Endo180 targeted antibody-drug conjugates
JP2026508860A (en) 2024-01-05 2026-03-13 ビーワン メディシンズ ワン ゲーエムベーハー Anti-FGFR2b antibody, conjugate, and method of use
WO2025149661A1 (en) 2024-01-10 2025-07-17 Genmab A/S Slitrk6 binding agents, conjugates thereof and methods of using the same
US20250381289A1 (en) 2024-02-29 2025-12-18 Genmab A/S Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
WO2025186213A1 (en) 2024-03-04 2025-09-12 Debiopharm International S.A. Combination of a wee1 inhibitor and a topoisomerase 1 inhibitor
WO2025185559A1 (en) * 2024-03-04 2025-09-12 杭州中美华东制药有限公司 Anti-fgfr2b antibody, antibody-drug conjugate thereof, and use thereof
WO2025228377A1 (en) * 2024-04-29 2025-11-06 上海甫弘生物医药有限公司 B7-h3/egfr binding molecule and medical use thereof
WO2025238587A1 (en) 2024-05-16 2025-11-20 Daiichi Sankyo Company, Limited Combination of anti-b7-h3 antibody-drug conjugate and androgen receptor signaling inhibitor
WO2025241867A1 (en) * 2024-05-24 2025-11-27 明慧医药（杭州）有限公司 Anti-b7-h4 antibody-drug conjugate and application thereof
WO2025260285A1 (en) 2024-06-19 2025-12-26 Duality Biologics (Suzhou) Co., Ltd. Antibody drug conjugate
WO2025262130A1 (en) 2024-06-19 2025-12-26 BioNTech SE Antibody drug conjugate
WO2026009133A1 (en) 2024-07-01 2026-01-08 Daiichi Sankyo Company, Limited Anti-b7-h3 antibody
WO2026015407A1 (en) * 2024-07-10 2026-01-15 Asieris Pharmaceuticals (Usa), Inc. Linkers for conjugates and methods of use thereof
WO2026021442A1 (en) * 2024-07-24 2026-01-29 上海翰森生物医药科技有限公司 Use of antibody-drug conjugate in preparation of drug for treating lung cancer
US20260048137A1 (en) 2024-08-16 2026-02-19 Ardeagen Corporation Anti-mesothelin antibody conjugates and methods of use thereof
WO2026052764A1 (en) 2024-09-06 2026-03-12 Astrazeneca Uk Limited A scoring method for an anti-trop2 antibody drug conjugate therapy
WO2026078620A1 (en) * 2024-10-11 2026-04-16 Medimmune Llc Cd22 antibody and drug conjugates and uses thereof

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DK0585287T3 (en) 1990-07-10 2000-04-17 Cambridge Antibody Tech Process for producing specific binding pair elements
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5658920A (en) 1991-01-16 1997-08-19 Daiichi Pharmaceutical Co., Ltd. Substituted 1H,12H-benz-[DE]pyrano[3',4':6,7] indolizino[1,2-B]quinoline-10,13(9H,15H)-dione compound
JP3008226B2 (en) 1991-01-16 2000-02-14 第一製薬株式会社 Hexacyclic compounds
JPH0559061U (en) 1991-04-18 1993-08-03 株式会社ケイヴイシー Ball valve
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
PT1024191E (en) 1991-12-02 2008-12-22 Medical Res Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
CA2131151A1 (en) 1992-03-24 1994-09-30 Kevin S. Johnson Methods for producing members of specific binding pairs
JP3359955B2 (en) 1992-07-16 2002-12-24 第一製薬株式会社 Antitumor agent
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
JPH0687746U (en) 1993-06-02 1994-12-22 株式会社ユニシアジェックス Hydraulic buffer reservoir tube structure
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
WO1995015388A1 (en) 1993-12-03 1995-06-08 Medical Research Council Recombinant binding proteins and peptides
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
JPH08337584A (en) 1995-04-10 1996-12-24 Dai Ichi Seiyaku Co Ltd Fused hexacyclic amino compound, pharmaceutical containing the same, and process for producing the same
US6504029B1 (en) 1995-04-10 2003-01-07 Daiichi Pharmaceutical Co., Ltd. Condensed-hexacyclic compounds and a process therefor
SG50747A1 (en) 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
CA2192725C (en) 1995-12-28 2004-04-20 Kenji Tsujihara Camptothecin derivatives
JPH1095802A (en) * 1995-12-28 1998-04-14 Tanabe Seiyaku Co Ltd Camptothecin derivatives
TW409058B (en) 1996-06-06 2000-10-21 Daiichi Seiyaku Co Method for preparation of a drug complex
TW527183B (en) 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
JPH1171280A (en) 1997-06-26 1999-03-16 Tanabe Seiyaku Co Ltd Pharmaceutical composition
JPH1192405A (en) * 1997-09-19 1999-04-06 Dai Ichi Seiyaku Co Ltd Medicinal complex
DK1071700T3 (en) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glycosylation modification of antibodies to enhance antibody-dependent cellular cytotoxicity
EA003398B1 (en) * 1998-05-22 2003-04-24 Дайити Фармасьютикал Ко., Лтд. Drug complex with polymeric carrier
CN1191093C (en) 1998-10-30 2005-03-02 第一制药株式会社 DDS compound and its determination method
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
JP2002060351A (en) 2000-03-22 2002-02-26 Dai Ichi Seiyaku Co Ltd Dds compound comprising drug having hydroxy group
US20030166513A1 (en) 2000-06-29 2003-09-04 Akihiro Imura Dds compound and process for the preparation thereof
AU2001271037A1 (en) 2000-07-13 2002-01-30 Daiichi Pharmaceutical Co., Ltd. Pharmaceutical compositions containing dds compounds
CA2953239A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
US7090843B1 (en) 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
TWI313609B (en) * 2001-08-21 2009-08-21 Mitsubishi Tanabe Pharma Corp Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor
IL161686A0 (en) 2001-11-01 2004-09-27 Uab Research Foundation Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents
CA2467242A1 (en) 2001-11-20 2003-05-30 Seattle Genetics, Inc. Treatment of immunological disorders using anti-cd30 antibodies
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
CA2478047C (en) 2002-03-01 2014-01-21 Immunomedics, Inc. Rs7 antibodies
CA2508831C (en) 2002-12-13 2012-05-01 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
US20040202666A1 (en) 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
US20050228007A1 (en) 2004-02-26 2005-10-13 Prakash Jagtap Isoquinoline derivatives and methods of use thereof
JP4942643B2 (en) 2004-03-02 2012-05-30 シアトル ジェネティックス， インコーポレイテッド Partially added antibodies and methods for conjugating them
JP4806680B2 (en) * 2004-05-19 2011-11-02 メダレックス インコーポレイテッド Self-sacrificing linker and drug conjugate
NZ579482A (en) 2004-06-01 2011-02-25 Genentech Inc Antibody drug conjugates and methods
JP2008521828A (en) 2004-11-29 2008-06-26 シアトル ジェネティックス， インコーポレイテッド Engineered antibodies and immunoconjugates
DE102005009099A1 (en) 2005-02-28 2006-08-31 Ktb Tumorforschungsgesellschaft Mbh New camptothecin-peptide derivatives, useful for treating cancer
DE102005009084A1 (en) 2005-02-28 2006-08-31 Ktb Tumorforschungsgesellschaft Mbh New anthracyclin-peptide derivatives, useful for treating cancer, especially of the prostate, are cleaved, in the tumor, by prostate-specific antigen to release active antitumor agent and are transported by serum albumen
JP5122441B2 (en) 2005-04-19 2013-01-16 シアトル ジェネティックス， インコーポレイテッド Humanized anti-CD70 binding agents and uses thereof
US7833979B2 (en) 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
JP2006316040A (en) 2005-05-13 2006-11-24 Genentech Inc HERCEPTIN® adjuvant therapy
CN101490087B (en) 2006-05-30 2013-11-06 健泰科生物技术公司 Antibodies and immunoconjugates and uses thereof
EP2032606B1 (en) 2006-05-30 2013-11-27 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
WO2007145306A1 (en) 2006-06-15 2007-12-21 National University Corporation Hokkaido University Element having long blood-circulating time which is degradable selectively in tumor tissue
ITMI20061473A1 (en) * 2006-07-26 2008-01-27 Indena Spa DERIVATIVES OF CAMPTOTECIN WITH ANTITUMORAL ACTIVITY
CA2673410A1 (en) 2006-12-21 2008-07-03 Schering Corporation Pyrrolo [3, 2-a] pyridine derivatives for inhibiting ksp kinesin activity
US20100143245A1 (en) * 2007-03-22 2010-06-10 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8h9
NZ610239A (en) 2008-04-30 2014-11-28 Immunogen Inc Cross-linkers and their uses
CA2750038C (en) 2009-02-05 2016-10-04 Oncoxx S.R.L. Anti-trop-2 monoclonal antibodies and uses thereof in the treatment and diagnosis of tumors
ES3000111T3 (en) 2009-02-13 2025-02-27 Immunomedics Inc Intermediates for preparing conjugates with an intracellularly-cleavable linkage
JP5829520B2 (en) 2009-08-20 2015-12-09 国立大学法人 千葉大学 Colchicine derivatives
JP2013505944A (en) 2009-09-24 2013-02-21 シアトル ジェネティックス， インコーポレイテッド DR5 ligand drug conjugate
MX2012013001A (en) 2010-05-13 2013-02-26 Univ Indiana Res & Tech Corp Glucagon superfamily peptides exhibiting nuclear hormone receptor activity.
US20110300150A1 (en) 2010-05-18 2011-12-08 Scott Eliasof Compositions and methods for treatment of autoimmune and other disease
RU2012157167A (en) 2010-07-12 2014-08-20 КовЭкс Текнолоджиз Айэлэнд Лимитед Polyfunctional antibody conjugates
US20120121615A1 (en) 2010-11-17 2012-05-17 Flygare John A Alaninyl maytansinol antibody conjugates
TWI495644B (en) 2011-11-11 2015-08-11 Rinat Neuroscience Corp Specific antibody of trophic cell surface antigen (Trop-2) and their use
SG11201403085PA (en) 2011-12-14 2014-10-30 Seattle Genetics Inc Fgfr antibody drug conjugates (adcs) and the use thereof
US20130280282A1 (en) 2012-04-24 2013-10-24 Daiichi Sankyo Co., Ltd. Dr5 ligand drug conjugates
CN104619350A (en) 2012-06-14 2015-05-13 Ambrx公司 Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides
US9517522B2 (en) * 2012-09-05 2016-12-13 Illinois Tool Works Inc. Self-aligning wire feeder assembly
ES2773710T3 (en) * 2012-10-11 2020-07-14 Daiichi Sankyo Co Ltd Linkers for antibody-drug conjugates
WO2014061277A1 (en) 2012-10-19 2014-04-24 第一三共株式会社 Antibody-drug conjugate produced by binding through linker having hydrophilic structure
EP2927227A4 (en) 2013-01-03 2015-12-30 Celltrion Inc Antibody-linker-drug conjugate, preparation method therefor, and anticancer drug composition containing same
CN103313390B (en) 2013-07-05 2016-01-20 江苏大学 A kind of WSN localization method based on double-movement beacon
IL310627B2 (en) * 2014-01-31 2026-04-01 Daiichi Sankyo Co Ltd Anti-her2 antibody-drug conjugates, compositions comprising same and uses thereof
EP3130608B1 (en) 2014-04-10 2019-09-04 Daiichi Sankyo Co., Ltd. (anti-her2 antibody)-drug conjugate
US20190386950A1 (en) 2017-02-24 2019-12-19 Gil Hoon Chang Message sharing system and method for interactive application

Also Published As

Publication number Publication date
KR20210132240A (en) 2021-11-03
PH12015500667A1 (en) 2015-05-18
RS60000B1 (en) 2020-04-30
JP6952835B2 (en) 2021-10-27
JP2018008982A (en) 2018-01-18
RU2664465C2 (en) 2018-08-17
RS57278B1 (en) 2018-08-31
CN104755494A (en) 2015-07-01
CY1120363T1 (en) 2019-07-10
JP7170812B2 (en) 2022-11-14
JP2017036274A (en) 2017-02-16
CN109081871A (en) 2018-12-25
CN113929738A (en) 2022-01-14
TW202033499A (en) 2020-09-16
TWI879656B (en) 2025-04-01
TWI870275B (en) 2025-01-11
US10973924B2 (en) 2021-04-13
US9808537B2 (en) 2017-11-07
AU2022203560B2 (en) 2025-02-06
EP2907824B1 (en) 2018-04-11
IL302494B1 (en) 2024-07-01
CA3021435C (en) 2021-10-12
LT2907824T (en) 2018-06-11
AU2025202668A1 (en) 2025-07-03
KR20200026323A (en) 2020-03-10
SI2907824T1 (en) 2018-06-29
DK3342785T3 (en) 2020-03-23
HRP20200353T1 (en) 2020-06-12
CY1122789T1 (en) 2021-05-05
SI3342785T1 (en) 2020-02-28
IL302494B2 (en) 2024-11-01
CA2885800A1 (en) 2014-04-17
RU2015113767A (en) 2016-12-10
TWI879658B (en) 2025-04-01
KR20180105271A (en) 2018-09-27
KR20230024433A (en) 2023-02-20
KR101901558B1 (en) 2018-09-21
RU2018128384A (en) 2018-10-02
TWI870276B (en) 2025-01-11
IL271760A (en) 2020-02-27
IL294622B2 (en) 2023-10-01
SG11201502887WA (en) 2015-05-28
AU2020200548A1 (en) 2020-02-13
JP5953378B2 (en) 2016-07-20
JP2016196484A (en) 2016-11-24
BR112015006521A2 (en) 2017-09-05
US20200282073A1 (en) 2020-09-10
TWI615152B (en) 2018-02-21
KR102709509B1 (en) 2024-09-24
KR102087017B1 (en) 2020-03-10
DK2907824T3 (en) 2018-07-23
TW202448464A (en) 2024-12-16
PH12015500667B1 (en) 2019-03-06
HK1256631A1 (en) 2019-09-27
KR102456726B1 (en) 2022-10-20
PT2907824T (en) 2018-06-07
US20240082413A1 (en) 2024-03-14
PL3342785T3 (en) 2020-09-07
TWI907646B (en) 2025-12-11
US20190008981A1 (en) 2019-01-10
AU2013328111A1 (en) 2015-03-12
SMT201800344T1 (en) 2018-09-13
TWI696611B (en) 2020-06-21
KR102584005B1 (en) 2023-09-27
TW202543629A (en) 2025-11-16
ES2671644T3 (en) 2018-06-07
CA2885800C (en) 2018-12-04
US20150297748A1 (en) 2015-10-22
CN113929738B (en) 2024-05-17
TW201420117A (en) 2014-06-01
MX364484B (en) 2019-04-29
CA3021435A1 (en) 2014-04-17
US20160279259A1 (en) 2016-09-29
NZ740948A (en) 2019-11-29
KR20150067149A (en) 2015-06-17
EP2907824A1 (en) 2015-08-19
TW202444429A (en) 2024-11-16
KR20230086800A (en) 2023-06-15
WO2014057687A1 (en) 2014-04-17
JP2023011799A (en) 2023-01-24
KR20180030734A (en) 2018-03-23
TW202448523A (en) 2024-12-16
TWI870274B (en) 2025-01-11
KR20230142808A (en) 2023-10-11
KR20240144454A (en) 2024-10-02
KR101841818B1 (en) 2018-03-26
US11633493B2 (en) 2023-04-25
MX2020010964A (en) 2020-11-09
KR20220146669A (en) 2022-11-01
TWI879657B (en) 2025-04-01
JP2024147681A (en) 2024-10-16
NZ746440A (en) 2019-11-29
US12186310B2 (en) 2025-01-07
JP6715888B2 (en) 2020-07-01
AU2018200308A1 (en) 2018-02-01
TWI877062B (en) 2025-03-11
EP3342785A1 (en) 2018-07-04
AU2022203560A1 (en) 2022-06-16
US10195288B2 (en) 2019-02-05
IL313147A (en) 2024-07-01
HK1210477A1 (en) 2016-04-22
PT3342785T (en) 2020-02-25
TWI879659B (en) 2025-04-01
ZA201900820B (en) 2022-08-31
TW202444428A (en) 2024-11-16
IL294622A (en) 2022-09-01
KR20210038728A (en) 2021-04-07
KR102498405B1 (en) 2023-02-09
CN104755494B (en) 2018-09-07
JP6030267B1 (en) 2016-11-24
JP7523506B2 (en) 2024-07-26
JP2020180124A (en) 2020-11-05
KR102369419B1 (en) 2022-03-02
NZ705394A (en) 2018-10-26
MX2019004502A (en) 2019-08-21
IL294622B1 (en) 2023-06-01
EP2907824A4 (en) 2016-06-08
JP6186045B2 (en) 2017-08-23
NZ746439A (en) 2019-11-29
KR20220029776A (en) 2022-03-08
HRP20180870T1 (en) 2018-07-13
TWI870273B (en) 2025-01-11
JP2018188455A (en) 2018-11-29
MY170251A (en) 2019-07-13
BR122021014365B1 (en) 2022-07-05
AU2013328111B2 (en) 2017-11-02
JP6371452B2 (en) 2018-08-08
EP3632471A1 (en) 2020-04-08
IL271760B (en) 2022-08-01
KR20220100727A (en) 2022-07-15
TW202233186A (en) 2022-09-01
JPWO2014057687A1 (en) 2016-09-05
KR102320907B1 (en) 2021-11-02
TWI650312B (en) 2019-02-11
TW201811746A (en) 2018-04-01
ZA201501825B (en) 2022-05-25
PH12018501433A1 (en) 2019-02-27
CN109081871B (en) 2023-07-14
HUE048748T2 (en) 2020-08-28
AU2018200308B2 (en) 2019-11-07
KR102237639B1 (en) 2021-04-07
TW202448463A (en) 2024-12-16
US20250049782A1 (en) 2025-02-13
IL302494A (en) 2023-06-01
IL238143A0 (en) 2015-05-31
TW202448521A (en) 2024-12-16
KR102853456B1 (en) 2025-09-01
HUE039000T2 (en) 2018-12-28
SG10201804788XA (en) 2018-07-30
RU2018128384A3 (en) 2021-12-20
TW201920098A (en) 2019-06-01
MX2015003903A (en) 2015-07-17
TWI877063B (en) 2025-03-11
EP3342785B1 (en) 2019-12-25
KR102417310B1 (en) 2022-07-05
KR20250130442A (en) 2025-09-01
TW202448522A (en) 2024-12-16
TW202448462A (en) 2024-12-16
KR102052319B1 (en) 2019-12-05
BR112015006521B1 (en) 2022-03-03
BR122021014396B1 (en) 2022-07-05
ES2773710T3 (en) 2020-07-14
TWI757740B (en) 2022-03-11
AU2020200548B2 (en) 2022-08-25
TR201809636T4 (en) 2018-07-23
PL2907824T3 (en) 2018-08-31
TW202444366A (en) 2024-11-16
KR102540419B1 (en) 2023-06-05
CN115960111A (en) 2023-04-14
LT3342785T (en) 2020-02-10
JP2022008581A (en) 2022-01-13
KR20190135559A (en) 2019-12-06
SMT202000138T1 (en) 2020-05-08
TW202444367A (en) 2024-11-16

Similar Documents

Publication Publication Date Title
HUS2500038I1 (en) Anti-trop2 antibody-drug conjugate
ZA201900820B (en) Antibody-drug conjugate
HUS2300020I1 (en) Pyrrolobenzodiazepine-antibody conjugates
ZA201502523B (en) Pyrrolobenzodiazepine-anitbody conjugates
SG10201605401WA (en) Antibody-drug conjugates
PT2920167T (en) Hydrazinyl-indole compounds and conjugates
HUE037604T2 (en) Drug-protein conjugates
IL237672A0 (en) Drug-protein conjugates
IL234604A (en) Carbohydrate-glycolipid conjugate vaccines
ZA201409119B (en) Polymer-nsaid conjugate
GB2508089B (en) Underpants

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed